Immuneering IMRX Stock
Immuneering Price Chart
Immuneering IMRX Financial and Trading Overview
| Immuneering stock price | 4.55 USD |
| Previous Close | 5.77 USD |
| Open | 5.66 USD |
| Bid | 4.04 USD x 200 |
| Ask | 5.6 USD x 200 |
| Day's Range | 4.34 - 5.68 USD |
| 52 Week Range | 1.66 - 10.08 USD |
| Volume | 8.86M USD |
| Avg. Volume | 1.14M USD |
| Market Cap | 290.81M USD |
| Beta (5Y Monthly) | 0.361 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.06 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17 USD |
IMRX Valuation Measures
| Enterprise Value | 220.34M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.3586633 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.408208 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -3.742 |
Trading Information
Immuneering Stock Price History
| Beta (5Y Monthly) | 0.361 |
| 52-Week Change | 208.55% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 10.08 USD |
| 52 Week Low | 1.66 USD |
| 50-Day Moving Average | 5.34 USD |
| 200-Day Moving Average | 5.81 USD |
IMRX Share Statistics
| Avg. Volume (3 month) | 1.14M USD |
| Avg. Daily Volume (10-Days) | 2.4M USD |
| Shares Outstanding | 64.7M |
| Float | 49.44M |
| Short Ratio | 13.09 |
| % Held by Insiders | 17.81% |
| % Held by Institutions | 47.30% |
| Shares Short | 9.89M |
| Short % of Float | 20.15% |
| Short % of Shares Outstanding | 15.29% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.88% |
| Return on Equity (ttm) | -43.83% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -58876424 USD |
| Net Income Avi to Common (ttm) | -54439660 USD |
| Diluted EPS (ttm) | -1.06 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 156.69M USD |
| Total Cash Per Share (mrq) | 2.42 USD |
| Total Debt (mrq) | 3.73M USD |
| Total Debt/Equity (mrq) | 1.81 USD |
| Current Ratio (mrq) | 32.449 |
| Book Value Per Share (mrq) | 3.192 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -49697400 USD |
| Levered Free Cash Flow (ttm) | -33193532 USD |
Profile of Immuneering
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 245 Main Street |
| ZIP | 02142 |
| Phone | 617 500 8080 |
| Website | https://immuneering.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 55 |
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Q&A For Immuneering Stock
What is a current IMRX stock price?
Immuneering IMRX stock price today per share is 4.55 USD.
How to purchase Immuneering stock?
You can buy IMRX shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immuneering?
The stock symbol or ticker of Immuneering is IMRX.
Which industry does the Immuneering company belong to?
The Immuneering industry is Biotechnology.
How many shares does Immuneering have in circulation?
The max supply of Immuneering shares is 64.7M.
What is Immuneering Price to Earnings Ratio (PE Ratio)?
Immuneering PE Ratio is now.
What was Immuneering earnings per share over the trailing 12 months (TTM)?
Immuneering EPS is -1.06 USD over the trailing 12 months.
Which sector does the Immuneering company belong to?
The Immuneering sector is Healthcare.
Immuneering IMRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| US Tech Global Market Composite NQGM | 2296 USD — |
-1.38
|
— — | 2280.64 USD — | 2323.09 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}